Loading
A phase 3 trial in lung cancer, run by Fudan University, now recruiting.
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) is a phase 3, interventional study registered as NCT06031246 by Fudan University, with a registry enrolment figure of 634 participants, started 2023-04-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: Selective Lymph Node Dissection. Conditions listed: Lung Adenocarcinoma; Lymph Node Metastasis. Primary outcome: 5-year overall survival. Lung eligibility wording from the registry: "Not receiving lung cancer surgery before;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.